Fluor Builds Diabetes API Manufacturing Facility for Novo Nordisk
PTSM: Pharmaceutical Technology Sourcing and Management
The $2-billion facility will be located in Clayton, North Carolina.
Fluor announced on Dec. 20, 2016 that it had been awarded an engineering, procurement, construction, and construction management contract by Novo Nordisk to build a new $2-billion 830,00-sq.-ft. diabetes API manufacturing facility in Clayton, North Carolina. Construction on the new facility is expected to be completed in mid-2019.
“Fluor is honored to have the opportunity to assist Novo Nordisk in building this world-class facility in North Carolina to provide modern treatments to diabetes patients,” said Juan G. Hernández, president of Fluor’s Life Sciences and Advanced Manufacturing business, in a press release. “This project is the single largest life-sciences facility investment in North Carolina’s history, which fits well with Fluor’s legacy of building numerous significant life sciences and manufacturing projects in the southeast United States.”
“Novo Nordisk selected Fluor for this critical project, the largest in our history, based on their strong safety culture, technical competence in the life sciences industry, and ability to deliver the full scope of work,” said Morten Nielsen, senior vice-president, Novo Nordisk, and responsible for the construction of the new facility, in the press release. “We look forward to continued strong cooperation for the success of this project.”
Source: Fluor
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
